论文部分内容阅读
目的观察西格列汀联合预混胰岛素治疗老年2型糖尿病临床疗效。方法将70例单纯使用诺和灵30R控制血糖不理想的老年2型糖尿病患者随机分为观察组和对照组。对照组32例,给予诺和灵30R,每日2次皮下注射;治疗组32例,在观察组的基础上增加西格列汀100mg,每日1次口服。治疗12周,观察治疗前后空腹血糖(FBG)、餐后2h血糖(2hPBG)、糖化血红蛋白(HbA1C)、每日胰岛素总量、低血糖发生情况。结果治疗前除胰岛素用量外,两组各项指标差异均无统计学差异(P>0.05)。治疗后两组FBG、2hPBG、HbA1C均下降;观察组每日胰岛用量减少,对照组增加,差异具有统计学意义(P<0.05)。结论西格列汀联合预混胰岛素可有效控制老年2型糖尿病患者血糖水平,还可减少胰岛素用量及低血糖风险,安全性更高。
Objective To observe the clinical efficacy of sitagliptin and premixed insulin in the treatment of type 2 diabetes in the elderly. Methods Seventy patients with type 2 diabetes mellitus who did not use Noropen 30R to control blood sugar were randomly divided into observation group and control group. The control group of 32 cases, noradren 30R, 2 times a day subcutaneous injection; the treatment group of 32 cases, on the basis of the observation group increased sitagliptin 100mg, 1 day orally. After 12 weeks of treatment, fasting blood glucose (FBG), postprandial 2h blood glucose (2hPBG), glycosylated hemoglobin (HbA1C), total daily insulin and hypoglycemia were observed before and after treatment. Results Before treatment, except for the amount of insulin, there was no significant difference between the two groups (P> 0.05). FBG, 2hPBG and HbA1C in two groups decreased after treatment. The amount of islets in observation group decreased daily and the control group increased, the difference was statistically significant (P <0.05). Conclusions Sitagliptin combined with premixed insulin can effectively control blood sugar level in elderly type 2 diabetic patients, reduce the risk of insulin dosage and hypoglycemia, and have higher safety.